Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Chemotherapy with PBPC Support for High-Risk Breast Cancer
NCT00001498Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 1996
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and doxorubicin in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Feasibility of administering induction, consolidation, and intensification therapy. Started Feb 1996; status: completed.
02
Drugs
paclitaxeldoxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00001498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001498.